DRD3

Across TCGA pan-cancer cohorts, DRD3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DRD3 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher DRD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DRD3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CESC, LUSC, and SKCM are the cancer types where DRD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.140	0.785	<.001	18	view →
LUSC	OS	Median	III,IV	0.221	0.702	<.001	12	view →
SKCM	OS	Median	III,IV	0.212	0.729	<.001	10	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
SARC	DFS	Median	All	0.024	0.591	<.001	3	view →
LUAD	DFS	Median	All	1.000	0.785	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DRD3–CESC (DFS)

Open the CESC breakdown →